Switch to:
Also traded in: Canada, Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash-to-Debt 1.38
OTCPK:IGXT's Cash-to-Debt is ranked lower than
77% of the 943 Companies
in the Global Biotechnology industry.

( Industry Median: 54.02 vs. OTCPK:IGXT: 1.38 )
Ranked among companies with meaningful Cash-to-Debt only.
OTCPK:IGXT' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.07  Med: N/A Max: No Debt
Current: 1.38
Equity-to-Asset 0.39
OTCPK:IGXT's Equity-to-Asset is ranked lower than
79% of the 709 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. OTCPK:IGXT: 0.39 )
Ranked among companies with meaningful Equity-to-Asset only.
OTCPK:IGXT' s Equity-to-Asset Range Over the Past 10 Years
Min: -0.16  Med: 0.57 Max: 0.85
Current: 0.39
-0.16
0.85
Piotroski F-Score: 4
Altman Z-Score: 2.02
Beneish M-Score: -4.03
WACC vs ROIC
11.33%
-22.30%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating Margin % -18.79
OTCPK:IGXT's Operating Margin % is ranked higher than
63% of the 737 Companies
in the Global Biotechnology industry.

( Industry Median: -92.31 vs. OTCPK:IGXT: -18.79 )
Ranked among companies with meaningful Operating Margin % only.
OTCPK:IGXT' s Operating Margin % Range Over the Past 10 Years
Min: -555.91  Med: -140.55 Max: 27.2
Current: -18.79
-555.91
27.2
Net Margin % -22.61
OTCPK:IGXT's Net Margin % is ranked higher than
62% of the 737 Companies
in the Global Biotechnology industry.

( Industry Median: -79.00 vs. OTCPK:IGXT: -22.61 )
Ranked among companies with meaningful Net Margin % only.
OTCPK:IGXT' s Net Margin % Range Over the Past 10 Years
Min: -557.27  Med: -162.29 Max: 25.34
Current: -22.61
-557.27
25.34
ROE % -24.16
OTCPK:IGXT's ROE % is ranked higher than
58% of the 853 Companies
in the Global Biotechnology industry.

( Industry Median: -36.35 vs. OTCPK:IGXT: -24.16 )
Ranked among companies with meaningful ROE % only.
OTCPK:IGXT' s ROE % Range Over the Past 10 Years
Min: -1461.46  Med: -82.57 Max: 25.47
Current: -24.16
-1461.46
25.47
ROA % -11.38
OTCPK:IGXT's ROA % is ranked higher than
66% of the 950 Companies
in the Global Biotechnology industry.

( Industry Median: -29.87 vs. OTCPK:IGXT: -11.38 )
Ranked among companies with meaningful ROA % only.
OTCPK:IGXT' s ROA % Range Over the Past 10 Years
Min: -193.99  Med: -64.12 Max: 16.99
Current: -11.38
-193.99
16.99
ROC (Joel Greenblatt) % -18.50
OTCPK:IGXT's ROC (Joel Greenblatt) % is ranked higher than
71% of the 907 Companies
in the Global Biotechnology industry.

( Industry Median: -394.49 vs. OTCPK:IGXT: -18.50 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
OTCPK:IGXT' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -808.25  Med: -259.09 Max: 54.17
Current: -18.5
-808.25
54.17
3-Year Revenue Growth Rate 65.80
OTCPK:IGXT's 3-Year Revenue Growth Rate is ranked higher than
91% of the 507 Companies
in the Global Biotechnology industry.

( Industry Median: 5.10 vs. OTCPK:IGXT: 65.80 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
OTCPK:IGXT' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 0  Med: -9.9 Max: 192.4
Current: 65.8
0
192.4
3-Year EBITDA Growth Rate -37.70
OTCPK:IGXT's 3-Year EBITDA Growth Rate is ranked lower than
87% of the 534 Companies
in the Global Biotechnology industry.

( Industry Median: -0.90 vs. OTCPK:IGXT: -37.70 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
OTCPK:IGXT' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: 0  Med: -12.25 Max: 129.6
Current: -37.7
0
129.6
3-Year EPS without NRI Growth Rate -12.60
OTCPK:IGXT's 3-Year EPS without NRI Growth Rate is ranked lower than
63% of the 519 Companies
in the Global Biotechnology industry.

( Industry Median: -2.90 vs. OTCPK:IGXT: -12.60 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
OTCPK:IGXT' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: 0  Med: -14.15 Max: 141
Current: -12.6
0
141
GuruFocus has detected 4 Warning Signs with Intelgenx Technologies Corp $OTCPK:IGXT.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» OTCPK:IGXT's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Insider Trades

Latest Guru Trades with OTCPK:IGXT

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:OTCPK:AQBT, OTCPK:COTQF, NAS:APOP, OTCPK:PTGEF, OTCPK:DYAI, NAS:TRIL, OTCPK:BLEVF, OTCPK:GRPOF, AMEX:AMPE, NAS:NVLS, NAS:NVET, NAS:MIRN, NAS:BLPH, NAS:DMPI, NAS:CLBS, NAS:DMTX, NAS:PBMD, NAS:APVO, OTCPK:IMROY, OTCPK:PRTX » details
Traded in other countries:IGX.Canada, 0IL.Germany,
Headquarter Location:Canada
Intelgenx Technologies Corp is a drug delivery company. The Company is engaged in the development of novel, orally administered drug delivery products based on its proprietary oral drug delivery technologies.

Intelgenx Technologies Corp., was incorporated in Delaware on July 27, 1999. The Company is a drug delivery company. It is engaged in the development of novel, orally administered drug delivery products based on its proprietary oral drug delivery technologies. Its product development efforts are based upon three platform technologies: Versafilm- an oral film technology, VersaTab- a multilayer tablet technology and AdVersa- a mucoadhesive tablet technology. The Oral Film technology consists of a thin (25-35 micron) polymeric film comprised of United States Pharmacopeia (USP) components that are approved by the FDA for use in food, pharmaceutical, and cosmetic products. Its multilayer tablet technology allows for the development of oral controlled-release products. The mucoadhesive tablet is a drug delivery system capable of adhering to the oral mucosa and releasing the drug onto the site of application at a controlled rate. The Company's product portfolio includes a blend of generic and branded products based on its proprietary delivery technology. Some of its products are INT0001/2004, INT0004/2006, INT0007/2006, and among others. The Company competes with pharmaceutical industries. Some of its competitors include Monosol Rx, Tesa-Labtec GmbH, BioDelivery Sciences International, Inc and LTS Lohmann Therapy Systems Corp. It is subject to change in governmental regulations, healthcare legislations, availability of financing, patent litigation and other factors.

Top Ranked Articles about Intelgenx Technologies Corp

RedHill Biopharma and IntelGenx Announce Marketing Approval of RIZAPORT® for Migraines in Luxembourg
IntelGenx and RedHill Biopharma Announce Signing of Definitive Agreement for Commercialization of RIZAPORT(TM) with Grupo Juste for Spain and Additional Potential Territories

SAINT-LAURENT, QUEBEC--(Marketwired - Jul 5, 2016) - IntelGenx Corp., (TSX VENTURE:IGX)(OTCQX:IGXT), and RedHill Biopharma Ltd. (NASDAQ:RDHL)(TASE:RDHL), today announced the signing of the definitive agreement with Grupo Juste S.A.Q.F. for the commercialization of RIZAPORT™, a unique oral thin film for the treatment of acute migraines, in the country of Spain. All commercial manufacturing of RIZAPORT™ will take place at IntelGenx' new state-of-the-art manufacturing facility in Canada. Full details of the financial terms of the agreement were not disclosed. Grupo Juste is a prominent private Spanish company with over 90 years of experience in the research, development and commercialization of proprietary pharmaceutical products, including migraine and other central nervous system (CNS) drugs, in Europe, Latin America and other territories. According to the definitive agreement, Grupo Juste has obtained exclusive rights to register, promote and distribute RIZAPORT™ in Spain. In exchange, IntelGenx and RedHill will receive upfront and milestone payments, together with a share of the net sales of RIZAPORT™. Commercial launch in Spain is estimated to take place in the second half of 2017. The initial term of the definitive agreement shall be for ten years from the date of first commercial sale of the product and shall automatically renew for one additional two-year term. The agreement will give Grupo Juste the right to market the product in the territory of Spain, with the right of first refusal for a predefined term for certain Latin American and Middle East countries. "We are most excited to be partnering with Grupo Juste as we believe it will bring patients in Spain and additional potential countries suffering with migraines an innovative solution using our VersaFilm™ technology," said Dr. Horst G. Zerbe, President and CEO of IntelGenx. "We view this as a significant achievement for IntelGenx and RedHill as this is the first commercial agreement of what we expect to be many opportunities in the future for RIZAPORT™. This will be the first commercial product manufactured in our new state-of-the-art manufacturing facility. IntelGenx and RedHill are actively pursuing several opportunities to bring RIZAPORT™ to new markets." Inés Juste, President of Grupo Juste added: "We are extremely satisfied to announce the planned arrival of this new formulation of a leading treatment for migraine. Our partners, IntelGenx and RedHill possess a deep knowledge in the pharmaceutical industry including strong leadership in innovative formulations that improve the compliance and the administration pattern of gold standard drugs. This agreement for commercialization should allow Grupo Juste to bring this new effective treatment to migraine patients in Spain and potentially some Latin American and Middle East countries and to reinforce its presence in Neurology." About RIZAPORT™:
RIZAPORT™ is a proprietary oral thin film formulation of rizatriptan benzoate, a 5-HT1 receptor agonist and the active drug in Merck & Co.'s Maxalt®. RIZAPORT™ 5mg and 10mg was approved for marketing in Germany in October 2015, under the European Decentralized Procedure. A New Drug Application for RIZAPORT™ was also filed with the U.S. FDA in 2013 and a CRL was received in 2014. Rizatriptan is considered one of the most effective oral triptans, a class of molecules that constricts blood vessels in the brain to relieve swelling and other migraine symptoms. The worldwide annual sales of triptans were estimated to have exceeded $870 million in 20141. RIZAPORT™ is based on IntelGenx's proprietary "VersaFilm™" technology. It dissolves rapidly and releases its active ingredient in the mouth, leading to efficient absorption of the drug through the gastrointestinal tract. The administration method of the RIZAPORT™ oral thin film, which does not require the patient to swallow a pill or consume water, along with its pleasant flavor, presents a potentially attractive therapeutic alternative for many migraine patients, including those who suffer from migraine-related nausea, estimated to be approximately 80% of the total migraine patient population. About Grupo Juste S.A.Q.F.:
Grupo JUSTE is a Spanish corporate group with more than 90 years' experience in research, development and distribution of drugs and active pharmaceutical ingredients. Its activity is aimed at improving the quality of life of patients, with the Central Nervous System therapies as one of its main areas of expertise since 1990 and a core strategic focus for the group. Grupo JUSTE has two areas of activity: the Pharmaceutical Division, with broad experience in Central Nervous System, Radiology, Gynaecology and Primary Care; and Justesa Imagen, a fine-chemicals company committed to the research, development and production of active pharmaceutical ingredients, with substantial expertise in contrast media. The group has a significant presence in all the major world markets, directly or through partnerships with leading pharmaceutical companies. For more information, please visit: www.grupojuste.com. About RedHill Biopharma Ltd.:
RedHill Biopharma Ltd. (NASDAQ:RDHL)(TASE:RDHL) is a biopharmaceutical company headquartered in Israel, primarily focused on the development and commercialization of late clinical-stage, proprietary, orally-administered, small molecule drugs for the treatment of inflammatory and gastrointestinal diseases and cancer. RedHill's current pipeline of proprietary products includes: (i) RHB-105 - an oral combination therapy for the treatment of Helicobacter pylori infection with successful results from a first Phase III study; (ii) RHB-104 - an oral combination therapy for the treatment of Crohn's disease with an ongoing first Phase III study and an ongoing proof-of-concept Phase IIa study for multiple sclerosis; (iii) BEKINDA™ (RHB-102) - a once-daily oral pill formulation of ondansetron with an ongoing Phase III study in the U.S. for acute gastroenteritis and gastritis and an ongoing Phase II study for IBS-D; (iv) RHB-106 - an encapsulated bowel preparation licensed to Salix Pharmaceuticals, Ltd.; (v) YELIVA™ (ABC294640) - a Phase II-stage, orally-administered, first-in-class SK2 selective inhibitor targeting multiple oncology, inflammatory and gastrointestinal indications; (vi) MESUPRON® - a Phase II-stage first-in-class uPA inhibitor, administered by oral capsule, targeting gastrointestinal and other solid tumors; (vii) RP101 - currently subject to an option-to-acquire by RedHill, RP101 is a Phase II-stage first-in-class Hsp27 inhibitor, administered by oral tablet, targeting pancreatic and other gastrointestinal cancers; (viii) RIZAPORT™ (RHB-103) - an oral thin film formulation of rizatriptan for acute migraines, with a U.S. NDA currently under discussion with the FDA and marketing authorization received in Germany in October 2015; and (ix) RHB-101 - a once-daily oral pill formulation of the cardio drug carvedilol.


2
EvaluatePharma 2013 WW annual sales report.



About IntelGenx:
IntelGenx is a leading drug delivery company focused on the development of innovative products based on its proprietary oral drug delivery technologies. Established in 2003, the Montreal-based company, listed on the TSX-V and OTC-QX, develops innovative oral drug delivery solutions based on its proprietary platform technologies, VersaFilm™, VersaTab™ and AdVersa™. IntelGenx has developed a broad and diverse product portfolio addressing unmet market needs and offering lifecycle management opportunities. Forfivo XL™, launched in 2012, is the first and only FDA approved once-daily bupropion HCl 450mg dose in a single tablet for the treatment of major depressive disorder. IntelGenx highly skilled team provides comprehensive pharmaceuticals services to pharmaceutical partners, including R&D, clinical monitoring, IP protection, analytical method development and regulatory services. IntelGenx state-of-the art manufacturing facility, established for the VersaFilm™ technology platform, supports lab-scale to pilot and commercial-scale production, offering full service capabilities to our clients. More information is available about the company at: www.intelgenx.com. Forward-Looking Statements:
This document may contain forward-looking information about IntelGenx' operating results and business prospects that involve substantial risks and uncertainties. Statements that are not purely historical are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended. These statements include, but are not limited to, statements about IntelGenx' plans, objectives, expectations, strategies, intentions or other characterizations of future events or circumstances and are generally identified by the words "may," "expects," "anticipates," "intends," "plans," "believes," "seeks," "estimates," "could," "would," and similar expressions. All forward looking statements are expressly qualified in their entirety by this cautionary statement. Because these forward-looking statements are subject to a number of risks and uncertainties, IntelGenx' actual results could differ materially from those expressed or implied by these forward looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those discussed under the heading "Risk Factors" in IntelGenx' annual report on Form 10-K, filed with the United States Securities and Exchange Commission and available at www.sec.gov, and also filed with Canadian securities regulatory authorities and www.sedar.com. IntelGenx assumes no obligation to update any such forward-looking statements. Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange), nor the OTCQX accepts responsibility for the adequacy or accuracy of this release. Source: IntelGenx Technologies Corp.





Edward Miller
Director, IR and Corporate Communications
IntelGenx Corp.
1 514-331-7440 (ext. 217)
[email protected]




Read more...
IntelGenx Reports Amendment of Stock Option Plan

SAINT LAURENT, QUEBEC--(Marketwired - May 12, 2016) - IntelGenx Technologies Corp. (TSX VENTURE:IGX)(OTCQX:IGXT) (the "Company" or "IntelGenx") reported today, that the Company's Board of Directors approved to amend the 2006 Stock Option Plan and to redesignate it as the "2016 Stock Option Plan". The number of shares available for issuance under the new Plan increased by 1,331,233 from 5,030,292 to 6,361,525, or 10% of the Company's issued and outstanding shares as of May 10, 2016. The 2016 Stock Option Plan is available on EDGAR and SEDAR for a complete review of the amendments. About IntelGenx: IntelGenx is a leading drug delivery company focused on the development of innovative products based on its proprietary oral drug delivery technologies. Established in 2003, the Montreal-based company, listed on the TSX-V and OTC-QX, develops innovative oral drug delivery solutions based on its proprietary platform technologies, VersaFilm™, VersaTab™ and AdVersa™. IntelGenx has developed a broad and diverse product portfolio addressing unmet market needs and offering lifecycle management opportunities. Forfivo XL™, launched in 2012, is the first and only FDA approved once-daily bupropion HCl 450mg dose in a single tablet for the treatment of major depressive disorder. IntelGenx highly skilled team provides comprehensive pharmaceuticals services to pharmaceutical partners, including R&D, clinical monitoring, IP protection, analytical method development and regulatory services. IntelGenx state-of-the art manufacturing facility, established for the VersaFilm™ technology platform, supports lab-scale to pilot and commercial-scale production, offering full service capabilities to our clients. More information is available about the company at: www.intelgenx.com. Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange), nor the OTCQX accepts responsibility for the adequacy or accuracy of this release.
Source: IntelGenx Technologies Corp.





Edward Miller
Director, Investor Relations and Corporate Communications
IntelGenx Corp.
1 514-331-7440 (ext. 217)
[email protected]




Read more...
IntelGenx Reports First Quarter 2016 Financial Results

SAINT LAURENT, QUEBEC--(Marketwired - May 10, 2016) - IntelGenx Corp. (TSX VENTURE:IGX)(OTCQX:IGXT) (the "Company" or "IntelGenx") today reported its first quarter 2016 financial results for the three-month period ended March 31, 2016. All amounts are in U.S. Dollars unless otherwise stated. The Company will host a conference call to provide a corporate update on Thursday, May 12th at 9:00 a.m. ET. Details of the conference call and webcast are listed below in this release. 2016 First Quarter Financial Highlights:

Revenues reached $818 thousand, an increase of 31% over the same period last year
Net comprehensive loss was ($707 thousand), compared to a net comprehensive loss of ($377 thousand) over the same period last year
Adjusted EBITDA loss was ($556 thousand), compared to adjusted EBITDA of $51 thousand over the same period last year
Cash and cash equivalents totaled $2.1 million as at March 31, 2016

Recent Operational Highlights:

Net sales of Forfivo XL® in the first quarter of 2016 increased by 39% to $2.5 million ($4.9 million gross) compared to net sales of $1.8 million ($3.3 million gross) over the same period last year
Submitted a patent application with the U.S. patent office for an oral film dosage form containing Loxapine for the treatment of anxiety and aggression in patients suffering from schizophrenia or bipolar 1 disorder
Granted from the USPTO a patent protecting Rizaport™, an oral thin film formulation of Rizatriptan benzoate for the treatment of acute migraines. This patent protects the composition of Rizaport™ and will be listed in the Orange Book upon approval of the product by the FDA
Announced a development and commercialization term sheet with a global pharmaceutical company for up to three products. If entered into, IntelGenx expects the definitive agreement to be finalized in the second quarter of 2016
Signed a commercialization term sheet for Rizaport™ with Grupo Juste for Spain and additional potential territories. If entered into, IntelGenx expects the definitive agreement to be finalized in the second quarter of 2016
Construction was successfully completed on the new state-of-the-art manufacturing and laboratory facilities which are expected to be fully operational by 2017. All of the new manufacturing equipment has been delivered and is being installed

"We made significant progress to start the year with the clear goal of transforming IntelGenx into a global leader of innovative pharmaceutical oral film development and manufacturing," said Dr. Horst G. Zerbe, President and CEO of IntelGenx. "Several key initiatives were successfully achieved with the completion of the construction of our state-of-the-art manufacturing facilities, the strengthening of our management team and the execution of two commercialization term sheets for a total of four products. The new team has been working hard together to build on each other's strengths in laying out IntelGenx' foundation for long-term growth. We very much look forward to communicating with shareholders on the future success of the organization." Financial Results: Total revenues for the three-month period ended March 31, 2016 amounted to $818 thousand, representing an increase of $193 thousand or 31% compared to $625 thousand for the three-month period ended March 31, 2015. The increase for the three-month period ended March 31, 2016 compared to last year's corresponding period is mainly attributable to the attainment of milestones, totaling $3 million from which $2.67 million was recorded in the last fiscal year and $333 thousand in the first quarter of 2016. Operating costs and expenses were $1.5 million for the three-month period ended March 31, 2016 compared to $610 thousand for the corresponding period of 2015. The increase for the three-month period ended March 31, 2016 is mainly attributable to an increase in Research and Development expenses of $364 thousand and Selling, General and Administrative of $498 thousand. For the first quarter of 2016, the Company generated an operating loss of ($706 thousand) compared to an operating gain of $15 thousand for the comparable period of 2015. Net comprehensive loss was ($707 thousand) or ($0.01) on a basic and diluted per share basis for the first quarter of 2016 compared to a net comprehensive loss of ($377 thousand) or ($0.00) on a basic and diluted per share basis for the comparable period of 2015. Cash on hand as at March 31, 2016 was $2.1 million, representing a decrease of ($798 thousand) compared with the balance of $2.9 million as at December 31, 2015. The decrease in cash relates to the comprehensive loss incurred in the first quarter. Conference Call Notice: IntelGenx will host a conference call to discuss its first quarter results on Thursday, May 12, 2016 at 9:00 a.m. ET. The dial-in number for the conference call is 1-877-201-0168 (Canada and United States) or (647) 788-4901 (International), conference ID 10318545. The call will be audio-cast live and archived for twelve months at: www.intelgenx.com. About IntelGenx: IntelGenx is a leading drug delivery company focused on the development of innovative products based on its proprietary oral drug delivery technologies. Established in 2003, the Montreal-based company, listed on the TSX-V and OTC-QX, develops innovative oral drug delivery solutions based on its proprietary platform technologies, VersaFilm™, VersaTab™ and AdVersa™. IntelGenx has developed a broad and diverse product portfolio addressing unmet market needs and offering lifecycle management opportunities. Forfivo XL™, launched in 2012, is the first and only FDA approved once-daily bupropion HCl 450mg dose in a single tablet for the treatment of major depressive disorder. IntelGenx highly skilled team provides comprehensive pharmaceuticals services to pharmaceutical partners, including R&D, clinical monitoring, IP protection, analytical method development and regulatory services. IntelGenx state-of-the art manufacturing facility, established for the VersaFilm™ technology platform, supports lab-scale to pilot and commercial-scale production, offering full service capabilities to our clients. More information is available about the company at: www.intelgenx.com. Forward-Looking Statements: This document may contain forward-looking information about IntelGenx' operating results and business prospects that involve substantial risks and uncertainties. Statements that are not purely historical are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended. These statements include, but are not limited to, statements about IntelGenx' plans, objectives, expectations, strategies, intentions or other characterizations of future events or circumstances and are generally identified by the words "may," "expects," "anticipates," "intends," "plans," "believes," "seeks," "estimates," "could," "would," and similar expressions. All forward looking statements are expressly qualified in their entirety by this cautionary statement. Because these forward-looking statements are subject to a number of risks and uncertainties, IntelGenx' actual results could differ materially from those expressed or implied by these forward looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those discussed under the heading "Risk Factors" in IntelGenx' annual report on Form 10-K, filed with the United States Securities and Exchange Commission and available at www.sec.gov, and also filed with Canadian securities regulatory authorities and www.sedar.com. IntelGenx assumes no obligation to update any such forward-looking statements. Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange), nor the OTCQX accepts responsibility for the adequacy or accuracy of this release. Source: IntelGenx Technologies Corp.





IntelGenx Corp.
Edward Miller
Director, Investor Relations and Corporate Communications
1 514-331-7440 (ext. 217)
[email protected]
www.intelgenx.com




Read more...
IntelGenx to Report First Quarter 2016 Financial Results on May 10, 2016

SAINT LAURENT, QUEBEC--(Marketwired - May 5, 2016) - IntelGenx Technologies Corp. (TSX VENTURE:IGX)(OTCQX:IGXT) ("IntelGenx"), today announced that it will release its first quarter 2016 financial results on May 10, 2016 at 4:00 p.m. ET followed by the annual general meeting of shareholders. A special presentation will then be made by Dr. Ludwig Aigner on "Rejuvenation of the aged brain - an example of drug delivery in drug repurposing." Shareholders are then invited to the company's grand opening of its brand new state-of-the-art manufacturing facilities where tours will be offered. About IntelGenx: IntelGenx is a leading drug delivery company focused on the development of innovative products based on its proprietary oral drug delivery technologies. Established in 2003, the Montreal-based company, listed on the TSX-V and OTC-QX, develops innovative oral drug delivery solutions based on its proprietary platform technologies, VersaFilm™, VersaTab™ and AdVersa™. IntelGenx has developed a broad and diverse product portfolio addressing unmet market needs and offering lifecycle management opportunities. Forfivo XL™, launched in 2012, is the first and only FDA approved once-daily bupropion HCl 450mg dose in a single tablet for the treatment of major depressive disorder. IntelGenx highly skilled team provides comprehensive pharmaceuticals services to pharmaceutical partners, including R&D, clinical monitoring, IP protection, analytical method development and regulatory services. IntelGenx state-of-the art manufacturing facility, established for the VersaFilm™ technology platform, supports lab-scale to pilot and commercial-scale production, offering full service capabilities to our clients. More information is available about the company at: www.intelgenx.com. Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange), nor the OTCQX accepts responsibility for the adequacy or accuracy of this release. Source: IntelGenx Technologies Corp.






Edward Miller
Director, IR and Corporate Communications
IntelGenx Corp.
1 514-331-7440 (ext. 217)
[email protected]




Read more...

Ratios

vs
industry
vs
history
Price-to-Owner-Earnings 240.00
IGXT's Price-to-Owner-Earnings is ranked lower than
88% of the 138 Companies
in the Global Biotechnology industry.

( Industry Median: 35.58 vs. IGXT: 240.00 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
IGXT' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 26.36  Med: 235 Max: 293.33
Current: 240
26.36
293.33
PB Ratio 9.46
IGXT's PB Ratio is ranked lower than
84% of the 844 Companies
in the Global Biotechnology industry.

( Industry Median: 3.75 vs. IGXT: 9.46 )
Ranked among companies with meaningful PB Ratio only.
IGXT' s PB Ratio Range Over the Past 10 Years
Min: 4.66  Med: 10.13 Max: 90
Current: 9.46
4.66
90
PS Ratio 9.11
IGXT's PS Ratio is ranked higher than
57% of the 685 Companies
in the Global Biotechnology industry.

( Industry Median: 12.47 vs. IGXT: 9.11 )
Ranked among companies with meaningful PS Ratio only.
IGXT' s PS Ratio Range Over the Past 10 Years
Min: 4.9  Med: 15.37 Max: 97.14
Current: 9.11
4.9
97.14
Price-to-Operating-Cash-Flow 40.01
IGXT's Price-to-Operating-Cash-Flow is ranked lower than
75% of the 191 Companies
in the Global Biotechnology industry.

( Industry Median: 21.01 vs. IGXT: 40.01 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
IGXT' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 14.87  Med: 41.39 Max: 58.89
Current: 40.01
14.87
58.89
EV-to-EBIT -48.39
IGXT's EV-to-EBIT is ranked lower than
99.99% of the 423 Companies
in the Global Biotechnology industry.

( Industry Median: 22.87 vs. IGXT: -48.39 )
Ranked among companies with meaningful EV-to-EBIT only.
IGXT' s EV-to-EBIT Range Over the Past 10 Years
Min: -58.7  Med: -12.4 Max: 375.1
Current: -48.39
-58.7
375.1
EV-to-EBITDA -101.45
IGXT's EV-to-EBITDA is ranked lower than
99.99% of the 466 Companies
in the Global Biotechnology industry.

( Industry Median: 17.12 vs. IGXT: -101.45 )
Ranked among companies with meaningful EV-to-EBITDA only.
IGXT' s EV-to-EBITDA Range Over the Past 10 Years
Min: -118.1  Med: -12.8 Max: 116.6
Current: -101.45
-118.1
116.6
Current Ratio 1.21
IGXT's Current Ratio is ranked lower than
85% of the 921 Companies
in the Global Biotechnology industry.

( Industry Median: 4.05 vs. IGXT: 1.21 )
Ranked among companies with meaningful Current Ratio only.
IGXT' s Current Ratio Range Over the Past 10 Years
Min: 1.07  Med: 3.13 Max: 6.45
Current: 1.21
1.07
6.45
Quick Ratio 1.21
IGXT's Quick Ratio is ranked lower than
81% of the 920 Companies
in the Global Biotechnology industry.

( Industry Median: 3.77 vs. IGXT: 1.21 )
Ranked among companies with meaningful Quick Ratio only.
IGXT' s Quick Ratio Range Over the Past 10 Years
Min: 1.07  Med: 3.13 Max: 6.45
Current: 1.21
1.07
6.45
Days Sales Outstanding 73.00
IGXT's Days Sales Outstanding is ranked lower than
58% of the 596 Companies
in the Global Biotechnology industry.

( Industry Median: 61.11 vs. IGXT: 73.00 )
Ranked among companies with meaningful Days Sales Outstanding only.
IGXT' s Days Sales Outstanding Range Over the Past 10 Years
Min: 55.44  Med: 130.94 Max: 390.59
Current: 73
55.44
390.59

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -2.10
IGXT's 3-Year Average Share Buyback Ratio is ranked higher than
85% of the 571 Companies
in the Global Biotechnology industry.

( Industry Median: -11.10 vs. IGXT: -2.10 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
IGXT' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -120.3  Med: -23.8 Max: -2.1
Current: -2.1
-120.3
-2.1

Valuation & Return

vs
industry
vs
history
Price-to-Tangible-Book 9.00
IGXT's Price-to-Tangible-Book is ranked lower than
78% of the 769 Companies
in the Global Biotechnology industry.

( Industry Median: 4.58 vs. IGXT: 9.00 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
IGXT' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 5.91  Med: 9.9 Max: 75
Current: 9
5.91
75
Price-to-Median-PS-Value 0.60
IGXT's Price-to-Median-PS-Value is ranked higher than
75% of the 584 Companies
in the Global Biotechnology industry.

( Industry Median: 0.98 vs. IGXT: 0.60 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
IGXT' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.44  Med: 0.89 Max: 1.97
Current: 0.6
0.44
1.97
Earnings Yield (Greenblatt) % -2.07
IGXT's Earnings Yield (Greenblatt) % is ranked higher than
62% of the 1272 Companies
in the Global Biotechnology industry.

( Industry Median: -6.37 vs. IGXT: -2.07 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
IGXT' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -2.16  Med: 2.35 Max: 5.1
Current: -2.07
-2.16
5.1

More Statistics

Revenue (TTM) (Mil) $5.22
EPS (TTM) $ -0.02
Beta1.63
Short Percentage of Float0.00%
52-Week Range $0.45 - 1.00
Shares Outstanding (Mil)65.42

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 6 8 17
EPS ($) -0.02 -0.03 0.05
EPS without NRI ($) -0.02 -0.03 0.05
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for OTCPK:IGXT

Headlines

Articles On GuruFocus.com
RedHill Biopharma and IntelGenx Announce Marketing Approval of RIZAPORT® for Migraines in Luxembo Apr 13 2017 
IntelGenx and RedHill Biopharma Announce Signing of Definitive Agreement for Commercialization of RI Jul 05 2016 
IntelGenx Reports Amendment of Stock Option Plan May 12 2016 
IntelGenx Reports First Quarter 2016 Financial Results May 10 2016 
IntelGenx to Report First Quarter 2016 Financial Results on May 10, 2016 May 05 2016 
IntelGenx and RedHill Biopharma Announce RIZAPORT(TM) Commercialization Term Sheet With Grupo Juste Mar 29 2016 
IntelGenx Announces Development and Commercialization Term Sheet with a Global Pharmaceutical Compan Mar 24 2016 
IntelGenx to Host Conference Call and Webcast of Fourth Quarter and Full-Year 2015 Financial Results Mar 09 2016 
IntelGenx Appoints Dr. Dana Matzen as Vice President, Business Development Mar 02 2016 
IntelGenx Announces USPTO Has Granted Patent Protecting RIZAPORT(TM) Oral Film for Migraines Feb 18 2016 

More From Other Websites
RedHill Biopharma and IntelGenx Announce Marketing Approval of RIZAPORT® for Migraines in... Apr 13 2017
IntelGenx and RedHill Biopharma Announce Marketing Approval of RIZAPORT(R) for Migraines in... Apr 13 2017
IntelGenx Files Preliminary Short Form Prospectus in Connection With a Proposed Offering of... Apr 05 2017
IntelGenx Presents at the 13th International Conference on Alzheimer's and Parkinson's Diseases Apr 04 2017
IntelGenx and Tetra Bio-Pharma Announce the Signing of a Definitive Agreement for the Development... Apr 03 2017
IntelGenx Technologies Corp. :IGXT-US: Earnings Analysis: Q4, 2016 By the Numbers : March 30, 2017 Mar 30 2017
IntelGenx Reports Fourth Quarter and Full-Year 2016 Financial Results Mar 28 2017
Oral Film Exclusivity Granted to IntelGenx' VersaFilm(TM) for Tadalafil Erectile Dysfunction Dosing... Mar 28 2017
IntelGenx to Report Fourth Quarter and Full Year 2016 Financial Results on March 28, 2017 -... Mar 21 2017
IntelGenx Engages Kilmer Lucas for Cross-Border Investor Relations Mar 13 2017
Research Reports Initiated on Healthcare Stocks Aphria, Antibe Therapeutics, BriaCell Therapeutics,... Mar 07 2017
IntelGenx and Tetra Bio-Pharma Announce the Signing of a Term Sheet for the Development and... Feb 09 2017
IntelGenx Presentation Now Available for On-Demand Viewing Feb 06 2017
Life Sciences & Healthcare Investor Conference & Webinar: Nasdaq and OTCQX Companies Present... Jan 30 2017
IntelGenx to Webcast, Live, at VirtualInvestorConferences.com February 2 Jan 30 2017
IntelGenx Grants Stock Options Jan 19 2017
IntelGenx Announces Definitive Agreement with Chemo Group for a Generic CNS Tablet Jan 04 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)